Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
600MPE | HR+ | Luminal | PS-1145 | IKK | NFKB | 5898.065 | uM | inf | inf | 0.9898 | 0.9898 | 0.0000 | 0.1430 | 0.0000 | 0.6845 | |
BT-20 | TNBC | Basal A | Methotrexate | DHFR | Metabolism | 5903.084 | uM | inf | inf | 1.0102 | 1.0102 | 0.0000 | 0.0105 | 0.0000 | 1.2088 | |
HCC1806 | TNBC | Basal A | Cisplatin | DNA cross-linker | DNA cross-linker | 9376.049 | uM | inf | inf | 0.9525 | 0.9525 | 0.0000 | 0.0225 | 0.0000 | 1.9229 | |
BT-474 | HER2amp | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5906.095 | uM | inf | inf | 1.0129 | 1.0129 | 0.0000 | 0.0481 | 0.0000 | 0.6731 | |
CAMA-1 | HR+ | Luminal | Celecoxib | COX2 | COX | 10473.136 | uM | inf | inf | 0.9467 | 0.9467 | 0.0000 | 0.0581 | 0.0000 | 1.3186 | |
BT-20 | TNBC | Basal A | FTase Inhibitor I | Ftase | MAPK | 11854.154 | uM | inf | inf | 0.8747 | 0.8747 | 0.0000 | 0.1104 | 0.0000 | 1.3146 | |
21NT | HER2amp | - | Ribavirin | 15383.211 | uM | inf | inf | 1.0074 | 1.0074 | 0.0000 | 0.0469 | 0.0000 | 1.0341 | |||
HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 12000.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0614 | 0.0000 | 0.6084 | |
BT-483 | HR+ | Luminal | Pevonedistat | NAE1 | NAE1 | 11855.135 | uM | inf | inf | 0.7998 | 0.7998 | 0.0000 | 0.2110 | 0.0000 | 0.6394 | |
600MPE | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5898.095 | uM | inf | inf | 0.3076 | 0.3076 | 0.0000 | 0.6877 | 0.0000 | 0.6975 | |
BT-483 | HR+ | Luminal | Selumetinib | MEK | MAPK | 11855.155 | uM | inf | inf | 0.7745 | 0.7745 | 0.0000 | 0.2804 | 0.0000 | 0.7873 | |
HCC1419 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 7440.065 | uM | inf | inf | 0.9343 | 0.9343 | 0.0000 | 0.1126 | 0.0000 | 0.5818 | |
BT-483 | HR+ | Luminal | PD184352 | MEK | MAPK | 11855.155 | uM | inf | inf | 0.7132 | 0.7132 | 0.0000 | 0.3205 | 0.0000 | 0.7873 | |
HCC1569 | HER2amp | Basal A | PD184352 | MEK | MAPK | 10872.155 | uM | inf | inf | 0.9297 | 0.9297 | 0.0000 | 0.0301 | 0.0000 | 1.5288 | |
BT-483 | HR+ | Luminal | PD184352 | MEK | MAPK | 11855.155 | uM | inf | inf | 0.7132 | 0.7132 | 0.0000 | 0.3205 | 0.0000 | 0.7873 | |
21MT-1 | HER2amp | - | Ribavirin | 15382.211 | uM | inf | inf | 0.9683 | 0.9683 | 0.0000 | 0.0416 | 0.0000 | 1.1714 | |||
HCC3153 | TNBC | Basal A | FTase Inhibitor I | Ftase | MAPK | 10577.142 | uM | inf | inf | 0.8245 | 0.8245 | 0.0000 | 0.1675 | 0.0000 | 1.0584 | |
MCF 10A | NM | Basal B | FTase Inhibitor I | Ftase | MAPK | 11056.154 | uM | inf | inf | 0.8956 | 0.8956 | 0.0000 | 0.0427 | 0.0000 | 2.9341 | |
HCC70 | TNBC | Basal A | FTase Inhibitor I | Ftase | MAPK | 12400.167 | uM | inf | inf | 1.0329 | 1.0329 | 0.0000 | 0.0088 | 0.0000 | 1.2627 | |
HCC1569 | HER2amp | Basal A | PD184352 | MEK | MAPK | 10872.155 | uM | inf | inf | 0.9297 | 0.9297 | 0.0000 | 0.0301 | 0.0000 | 1.5288 | |
600MPE | HR+ | Luminal | PS-1145 | IKK | NFKB | 5899.065 | uM | inf | inf | 0.8491 | 0.8491 | 0.0000 | 0.1182 | 0.0000 | 1.0946 | |
HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 11849.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0324 | 0.0000 | 1.5253 | |
BT-483 | HR+ | Luminal | ICRF-193 | TOP2 | TOP | 11855.157 | uM | inf | inf | 0.7596 | 0.7596 | 0.0000 | 0.2419 | 0.0000 | 0.7986 | |
SK-BR-3 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 11851.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0487 | 0.0000 | 1.4873 | |
SK-BR-3 | HER2amp | Luminal | FTase Inhibitor I | Ftase | MAPK | 11851.154 | uM | inf | inf | 0.9971 | 0.9971 | 0.0000 | 0.0156 | 0.0000 | 1.1765 |